OTSUKA PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.otsuka.co.jp
A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 106
- Registration Number
- NCT01942161
Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2016-01-01
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT01895322
A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
- First Posted Date
- 2013-06-12
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT01876381
A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer
- First Posted Date
- 2013-03-01
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT01801930
A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT01737931
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Kyeonggi-do, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)
- First Posted Date
- 2012-09-12
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 43
- Registration Number
- NCT01684202
Phase 2 Study to Evaluate the Preliminary Performance of the C13-URA Breath Test Kit in Dyspeptic Subjects
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT01677338
- Locations
- 🇺🇸
Compass Research, Orlando, Florida, United States
🇺🇸Dartmouth-Hitchcock Medical Center, Gastroenterology and Hepatology, Lebanon, New Hampshire, United States
Confirmatory Study of OPC-12759 Ophthalmic Solution
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 209
- Registration Number
- NCT01660256
- Locations
- 🇯🇵
Kansai Region, Kansai Region, Japan
🇯🇵Kanto region, Kanto Region, Japan
🇯🇵Kyushu region, Kyushu Region, Japan
A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT01634243
A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 321
- Registration Number
- NCT01631825
© Copyright 2024. All Rights Reserved by MedPath